Dendreon Corp (DNDN): Today's Featured Drugs Winner

Dendreon ( DNDN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.9%. By the end of trading, Dendreon rose 32 cents (5.2%) to $6.53 on heavy volume. Throughout the day, 12.5 million shares of Dendreon exchanged hands as compared to its average daily volume of 6.4 million shares. The stock ranged in a price between $6.19-$7.20 after having opened the day at $6.21 as compared to the previous trading day's close of $6.21. Other companies within the Drugs industry that increased today were: Sarepta Therapeutics ( SRPT), up 146.2%, Catalyst Pharmaceutical Partners ( CPRX), up 22.7%, Aoxing Pharmaceutical Company ( AXN), up 13.1%, and Prima Biomed Ltd. ADR ( PBMD), up 10.2%.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Dendreon has a market cap of $1 billion and is part of the health care sector. Shares are down 18.3% year to date as of the close of trading on Monday. Currently there are three analysts that rate Dendreon a buy, five analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Dendreon as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management.

On the negative front, Savient Pharmaceuticals ( SVNT), down 17.9%, K-V Pharmaceutical Company ( KV.A), down 17.1%, CytRx Corporation ( CYTR), down 15.3%, and Elan ( ELN), down 14.7%, were all laggards within the drugs industry with Pfizer ( PFE) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes